News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma, University of Arkansas for Medical Sciences Study



10/17/2007 9:37:04 AM

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Skin cancer specialists at the University of Arkansas for Medical Sciences’ (UAMS) Winthrop P. Rockefeller Cancer Institute (formerly the Arkansas Cancer Research Center) are recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. If Allovectin-7® is found to be safe and effective in clinical trials, it may offer patients a new option for fighting advanced melanoma (stage 3 or stage 4). Safety and efficacy data from a Phase 2 clinical trial of Allovectin-7® were presented at the 2006 American Society of Clinical Oncology (ASCO) meeting. The ongoing Phase 3 study is designed to determine whether more patients with advanced melanoma respond favorably to Allovectin-7® alone than to current standard chemotherapy alone. To find out whether you or someone you know qualifies for the study, please visit www.melanomatrial.com.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES